2Meltzer HY.The role of serotonin in antipsychotic drug action[J].Neuropsychopharmacology,1999,21(2):106S-115S.
3Kongsamut S,Roehr JE,Cai J,et al.Iloperidone binding to human and rat dopamine and 5-HT receptors[J].Eur J Pharmacol,1996,317(2-3):417-423.
4Kalkman HO,Subramanian N,Hoyer D.Extended radioligand binding profile of iloperidone:A broad spectrum dopemine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders[J].Neuropsychopharmacology,2001,25(6):904-914.
5Richelson E,Souder T.Binding of antipsychotic drugs to human brain receptors:Focus on newer generation compounds[J].Life sci,2000,68(1):29-39.
6Kalkman HO,Feuerbach D,Lotscher E,et al.Functional characterization of the novel antipsychotic iloperidone at human D2,D3,alpha2C,5-HT6,and 5-HT1A receptors[J].Life Sci,2003,73(7):1151-1159.
7Fanapt(iloperidone tablets)[EB/OL].Drug information http://www.rxlist.com/fanapt-drug.html.
8US Food and Drug Administration.Iloperidone,Approval Hystory[J].NDA 022192,review:(accessed September 2009).
9Sainati SM,Hubbard JW,Chi E,et al.Safety,tolerability,and effect of food on the pharmacokinetics of iloperidone(HP873),a potential atypical antipsychotic[J].J Clin Pharmacol,1995,35(7):713-720.Erratum in:J Clin Pharmacol,1996,36(1):92.
10Jain KK.An assessment of iloperidone for the treatment of schizophrenia[J].Expert Opin Investig Drugs,2000,9(12):2935-2943.
5CITROME L. lloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second- generation antipsychotic[J], lnt J Clin Pract, 2009, 63(8): 1237- 1248.
6CITROME L, MENG X, HOCHFELD M. Efficacy of iloperidone in schizophrenia: A PANSS five-factor analysis[J]. Schizophr Res, 2011, 131(1-3): 75-81.
7CRABTREE BL, MONTGOMERY J. lloperidone for the mana- gement of adults with schizophrenia [J]. Clin Ther, 2011, 33(3 ) : 330-345.
8CITROME L, MENG X, HOCHFELD M, et al. Efllcacy of iloperidone in the short-term treatment of schizophrenia: a posthoc analysis of pooled patient data from four phase Ill , placebo and active controlled trials[J]. Hum Psychopharmacol, 2012, 27 (l): 24-32.
9MUTLIB AE, KLEIN JT. Application of liquid chromatography/ mass spectrometry in accelerating |he identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone[J]. J Pharmacol Exp Ther, 1998, 286 (3): 1285- 1293.
10MUTLIB AE, STRUPCZEWSKI JT. Application of hyphenated LC/NMR and LC/MS techniques in rapid identification of in 1'itro and in vivo metabolites of iloperidone[J]. Drug Metab and Dispos, 1995, 23(9): 951-964.
